TCR triggering of anti-melanoma CD8+ T cells in SLAMF6 knockout mice resulted in a robust effector phenotype, increased IFN-γ production, enhanced cytolysis, and improved outcomes in the adoptive transfer of SLAMF6-/- anti-melanoma CD8+ T cells to treat existing melanoma (114). This evidence concerns the gene CD8A and melanoma.